mRNA were observed in NP compared with UPM. DP and CRTH2 mRNA levels were not only positively and inversely correlated with levels of h-PGDS but also with eotaxin, respectively. Furthermore, addition of PGD 2 significantly increased DP expression and conversely reduced CRTH2 expression in UPM. Conclusions: These results suggest that distinct expression of DP and CRTH2 is associated with the pathophysiology of CRS, including NP formation, and the expression of these receptors may be regulated by h-PGDS and PGD 2 .
. Among prostaglandins (PGs), PGD 2 is thought to mediate airway inflammation [8] [9] [10] . We recently reported that hematopoietic-type PGD 2 synthase (h-PGDS) may play an important role in the pathophysiology of CRS [6] . In this report, greater levels of h-PGDS mRNA were observed in NP compared with uncinate process mucosae (UPM). h-PGDS mRNA levels were significantly increased in asthmatics compared with non-asthmatics. More importantly, levels of h-PGDS were not only positively correlated with the degree of infiltration by EG2+ eosinophils, but also with radiological severity of sinusitis, suggesting that h-PGDS displays a proinflammatory role in the pathophysiology of CRS [6] . PGD 2 acts via the D-prostanoid receptor (DP) and chemoattractant receptor-homologous molecule expressed on Th 2 cells (CRTH2). The expression patterns and signaling pathways utilized by DP and CRTH2 are different, suggesting that they have distinct roles in airway inflammation [11, 12] . For example, DP-induced signals promote eosinophil survival and chemotaxis, whereas signals induced by CRTH2 mediate shape changes, chemotaxis and degranulation by eosinophils [13, 14] . Although both DP and CRTH2 are expressed in sinonasal tissue [15] , it remains unclear whether these two receptors display a differential role in the pathogenesis of CRS.
In the present study, we sought to determine the expression of DP and CRTH2 mRNA in NP and UPM and investigated the characterization of these receptors in the pathogenesis of CRS, especially in relation to mRNA levels of h-PGDS. We believe that the results presented here support the distinct role of PGD 2 receptors in the pathophysiology of CRS, especially NP formation, and may provide a basis for future therapeutic approaches aimed at the control of PGD 2 receptors to limit eosinophilic airway inflammation.
Patients and Methods

Patients and Tissue Sampling
Thirty-four Japanese patients with CRS were enrolled. In brief, 22 of 34 CRS patients had NP (group CRS-NP) and the remainder (n = 12) had no visible polyps in the middle meatus (group CRS). CRS and CRS-NP were defined using the diagnostic criteria established by Benninger et al. [1] . Nine patients were asthmatic, and all of them had NP. Among the 9 asthmatic patients, two were thought to have aspirin sensitivity based on a clear-cut history of asthma attacks precipitated by non-steroidal anti-inflammatory drugs. All patients were resistant to medical treatment, including macrolide therapy, and thus had endonasal sinus surgery; then either NP or UPM were sampled as described previously [6] . None of the participants received systemic steroids for a period of at least 8 weeks prior to surgery, and none received pharmacotherapy for sinusitis, e.g. macrolide antibiotics or intranasal steroids, for a period of at least 3 weeks prior to surgery. Before surgery, serum total IgE levels were assessed and blood eosinophils were counted in every patient. To evaluate the radiological severity of sinusitis, CT examination was performed, and severity was graded according to the system of Lund and Mackay [16] for each patient. Eleven of 24 patients showed elevated serum total IgE levels ( 1 170 IU/ml) and were regarded as atopic. The clinical characteristics of both patient groups are shown in table 1 . All patients in this study provided informed consent before their participation, and the study was approved by the Human Research Committee of the Okayama University Graduate School of Medicine and Dentistry.
Immunohistochemistry
Immunohistochemical staining for eosinophils was performed using EG2 antibody (Pharmacia, Uppsala, Sweden) as described previously [6] . Positive cells were counted in five highpower fields (10 ! 40) where the highest cellular infiltration was seen, from which the average number of positive cells was determined. Immunohistochemical staining for DP and CRTH2 protein was also performed. Rabbit anti-human DP polyclonal antibody and rabbit anti-human CRTH2 polyclonal antibody were purchased from Cayman (Ann Arbor, Mich., USA) and GeneTex (San Antonio, Tex., USA), respectively. In brief, paraffin-embedded tissue was sectioned into 4-m slices, deparaffinized and rehydrated. For the detection of DP, sections were treated with trypsin. Endogenous peroxidase activity was quenched with 0.3% H 2 O 2 , and non-specific protein binding was blocked with 5% normal goat serum for 60 min. Thereafter, tissue sections were incubated with primary antibodies (DP: ! 200 dilution; CRTH2: ! 500 dilution) or control (Universal Negative Control, Rabbit; Dako, Carpinteria, Calif., USA) at 4 ° C overnight. A Histofine MAX-PO (Nichirei Bioscience, Tokyo, Japan) with diaminobenzidine substrate was used according to the manufacturer's instructions. The sections were nuclear stained with hematoxylin and examined under a light microscope. 
Real-Time Quantitative PCR
Real-time quantitative PCR was applied as described previously [6] . In brief, the assay was performed using a Chromo4 realtime PCR detector (Bio-Rad Laboratories, Hercules, Calif., USA) with QuantiTect SYBR Green PCR (Qiagen, Hilden, Germany). The primers used for PCR had the following sequences and product sizes: h-PGDS, forward 5 -GAGAGCAGAAATTATTCGT-TAC-3 and reverse 5 -CCAGAGTGTCCACAATAGCA-3 (248 bp); DP, forward 5 -GCAACCTCTATGCGATGCA-3 and reverse 5 -CAAGGCTCGGAGGTCTTCT-3 (260 bp); CRTH2, forward 5 -CTACAATGTGCTGCTCCTGAA-3 and reverse 5 -CAGGTGAGCACGTAGAGC-3 (375 bp); GAPDH, forward 5 -ACCACAGTCCATGCCATCAC-3 and reverse 5 -TCCACCAC-CCTGTTGCTGTA-3 (452 bp); IL-5, forward 5 -TGCCTACGT-GTATGCCTCC-3 and reverse 5 -GAATTGGTTTACTCTCC-GTC-3 (304 bp); eotaxin, forward 5 -CTCCGCAGCACTT-CTGTGGC-3 and reverse 5 -GGTCGGCACAGATATCCTTG-3 (218 bp), and RANTES, forward 5 -GTCATCCTCATTG-CTACTGC-3 and reverse 5 -GGTGAGAAACAGCGACTGC-TG-3 (172 bp). The 25-l reaction mixture contained 300 n M each of forward and reverse primers, as well as QuantiTect SYBR Green PCR Master Mix (Qiagen), and 1 l of cDNA from a 20-l volume of RT reaction mixture. Amplification was performed as follows: initial denaturation at 95 ° C for 15 min, 40 cycles of denaturation at 94 ° C for 15 s, annealing at 58 ° C, except for CRTH2 at 56 ° C, for 30 s and extension at 72 ° C for 30 s. The amplified material was verified as single by examining the dissociation curve and ensuring it was of appropriate molecular weight by electrophoresis using 1.5% agarose gel, followed by sequencing. GAPDH from serially diluted plasmid DNA was amplified and a standard curve was plotted. The same method was used to quantify the genes of interest. The amounts of GAPDH were used as an internal control. The absolute copy number for each sample was calculated, and samples were reported as copy numbers relative to GAPDH.
In situ Hybridization
The expression and distribution of DP and CRTH2 mRNAs in NP or UPM were observed by in situ hybridization (ISH), as previously described [17] . Briefly, NP or UPM were rapidly fixed overnight in 4% paraformaldehyde/0.1 M PBS (pH 7.4) at 4 ° C. Then, tissue samples were embedded in paraffin and serial sections were cut at 4-m thickness. Human DP and CRTH2 digoxigenin (DIG)-11-uridine 5 -triphosphate-labeled single-strand RNA probes were prepared using a DIG labeling kit (Roche Diagnostics, Penzberg, Germany), according to the manufacturer's instructions. Hybridization was performed at 55 ° C for 16 h. Then, excess probe was washed out using 2 times SSC/50% formamide at 50 ° C for 30 min and 2 times SSC at 50 ° C for 30 min. Sections were blocked with 1.5% blocking reagent. Then sections were incubated with alkaline phosphatase-conjugated anti-DIG antibody ( ! 800 dilution) for 30 min. Signals were visualized by treatment with nitroblue tetrazolium salt and 5-bromo-4-chloro-3-indolyl phosphate p -toluidine salt at 37 ° C. The sections were nuclear stained with methyl green and examined under a light microscope.
Sense and anti-sense DIG-11-UTP labeled RNA probes for DP and CRTH2 were prepared as follows. Total RNA was extracted from NP. A 237-and a 945-bp fragment of human cDNA for DP (bases 793-1029; GenBank accession No. NM_000953) and CRTH2 (bases 91-1035; GenBank accession No. NM_004778), respectively, were obtained by RT-PCR and subcloned into plasmid Bluescript II KS(-). The sequence of RT-PCR primers for DP and CRTH2 were described as above. Sense probes were used for negative controls.
Measurement of PGD 2 in Middle Meatus Secretions
Two paper disks originally distributed as a control in nasal provocation tests with house dust mites (3-mm diameter; Torii, Tokyo, Japan) were placed in the middle meatus of CRS patients with (n = 10) and without (n = 9) NP for 3 min. Then they were collected and stored at -80 ° C until assayed. Secretions were extracted by 400 l of PBS including 10 M of indomethacin. Preliminary experiments reveal that 1 85% of protein could be recovered from the disks by this extraction. PGD 2 in the extraction was assessed using the Prostaglandin D 2 -MOX EIA kit (Cayman), according to the manufacturer's instructions. The detection limit of this assay is 23.4 pg/ml. The concentrations of total protein in the extraction from middle meatus secretions were determined by applying the bicinchoninic acid assay according to the manufacturer's instructions (Pierce, Rockford, Ill., USA). The concentration of PGD 2 was divided by the concentration of total protein (mg of total protein/ml) for standardization.
Effect of PGD 2 on DP and CRTH2 Expression UPM (n = 6) was sampled from patients with CRS, cut into small pieces (3 ! 5 mm) and placed in 48-well culture plates (Asahi Glass, Tokyo, Japan). The samples were incubated with 10 -6 M PGD 2 (Cayman) or control buffer (DMSO; Sigma, St. Louis, Mo., USA) in RPMI-1640 supplemented with 10% FCS (Sigma), 100 U/ml penicillin, 100 mg/ml streptomycin and 20 n M L-glutamine (Sigma) in 5% CO 2 /air mixture. After 12 h of incubation, the samples were immediately soaked in RNAlater TM RNA stabilization reagent (Qiagen) and stored at -30 ° C until use. The amounts of DP and CRTH2 mRNA in cultured UPM were determined by real-time quantitative PCR as described above. Fold-changes from control were given.
Statistical Analysis
Values are given as medians. Non-parametric Mann-Whitney's U test was used for intergroup comparisons, and the Wilcoxon's signed-rank test was used for intragroup analysis. Multiple comparisons were analyzed by the Bonferroni/Dunn test. Correlation analysis was performed using Spearman's rank correlation coefficient. A level of p ! 0.05 was considered to be statistically significant. Statistical analyses were performed using StatView TM software (version 4.5; Abacus Conceps, Berkeley, Calif., USA).
Results
Expression of DP and CRTH2 mRNA and Protein in NP and UPM Using ISH, the expression and distribution of DP and CRTH2 mRNA in NP and UPM were examined. The hybridization signal for DP mRNA was observed in both NP and UPM, with brighter expression in NP than UPM ( fig. 1 ) . DP mRNA was expressed in various cell types, including ciliated columnar epithelia, vascular endothelial cells, glands and infiltrating inflammatory cells. The hybridization signal for CRTH2 mRNA was seen in UPM ( fig. 2 ). CRTH2 mRNA was mainly expressed in inflammatory cells. Additionally, CRTH2 mRNA was also expressed in a part of the glands. On the other hand, fewer CRTH2 mRNA signals were observed in NP. Using sense probes, non-specific staining was observed in gland mucins in both DP and CRTH2 ( fig. 1 , 2 ) . Similar expression of PGD 2 receptors was confirmed at protein level ( fig. 3 ).
Relative Amounts of DP and CRTH2 mRNA in NP and UPM and Their Pathophysiological Characterization Similar to the ISH results, real-time PCR revealed that the DP mRNA level in NP was significantly higher than in UPM (p = 0.010, fig. 4 a) . Conversely, the level of CRTH2 mRNA in NP was significantly lower than that in UPM (p ! 0.001, fig. 4 b) .
Pathophysiologically, significant differences in the relative amounts of DP and CRTH2 mRNA in CRS were noted. With regard to asthma, we can divide samples into three subgroups: UPM (n = 12), NP without asthma (n = 13) and NP with asthma (n = 9). Multiple comparisons using the Bonferroni/Dunn test indicated that the DP mRNA levels were not significantly different among the three subgroups. However, CRTH2 mRNA levels were significantly lower in NP without asthma (p = 0.002) and NP with asthma (p = 0.003) than in UPM. On the other hand, CRTH2 mRNA levels were similar in NP regardless of the presence of asthma (p = 0.838). With regard to the atopic status, samples can be ascribed to one of four subgroups: UPM without atopy (n = 9), UPM with atopy (n = 3), NP without atopy (n = 14) and NP with atopy (n = 8). The Bonferroni/Dunn test showed that DP mRNA levels were not significantly different among the four subgroups. However, CRTH2 mRNA levels were significantly lower in NP without atopy (p = 0.002) and NP with atopy (p = 0.003) than in UPM without atopy. There was no correlation between the DP mRNA level and radiological severity of sinusitis ( = 0.019, p = 0.936). However, there was a significant inverse correlation between the CRTH2 mRNA level and the CT score ( = -0.516, p ! 0.001).
In NP, no significant correlation was seen between the degree of eosinophilia, determined by immunohistochemistry using EG2, and the DP ( = -0.120, p = 0.578) or CRTH2 ( = 0.240, p = 0.810) mRNA levels. Additionally, no significant correlation was observed between the DP mRNA level ( = -0.278, p = 0.202) or CRTH2 ( = 0.419, p = 0.321) and blood eosinophil counts.
Correlation between PGD 2 Receptor and h-PGDS Levels
Next, we examined the correlations between the local PGD 2 receptor and h-PGDS levels in CRS. DP levels were weakly and positively correlated with h-PGDS levels ( = 0.379, p = 0.020, fig. 5 a) . Interestingly, CRTH2 levels were significantly and inversely correlated with h-PGDS levels ( = -0.600, p ! 0.001, fig. 5 b) . There are two distinct populations: one population with high CRTH2 expression (mainly CRS patients without NP, n = 15) and the other population with low CRTH2 expression and higher h-PGDS expression (n = 19). When correlation analysis was performed with the two populations separately, no correlation between h-PGDS and CRTH2 was seen in either population (high CRTH2 expression group: = -0.325, p = 0.224, low CRTH2 expression group: = 0.275, p = 0.100). The level of PGD 2 in middle meatus secretions was significantly higher in CRS patients with NP compared with CRS patients without NP (p = 0.025, fig. 6 ).
Correlation between the Expression of PGD 2 Receptors and Eosinophil-Associated Cytokines/Chemokines
Correlations between the mRNA levels of PGD 2 receptors and eosinophil inflammation markers were analyzed. A significant positive correlation between DP and eotaxin levels ( = 0.532, p = 0.002, fig. 7 ISH staining of DP mRNA in sinonasal tissues. Sections of UPM and NP were reacted with DP antisense probes. As controls, the sections were reacted with DP sense probes. Typical expressions in ciliated columnar epithelia, vascular endothelial cells, glands and infiltrating inflammatory cells were shown. Immunohistochemical staining of DP ( a ) and CRTH2 ( b ) protein in NP. Sections were reacted with rabbit polyclonal antibody against DP ( a ), rabbit polyclonal antibody against CRTH2 ( b ) or respective controls ( c : trypsin retrieval; d : no retrieval), after which they were stained using a Histofine MAX-PO with a diaminobenzidine substrate, as described. Scale bar = 50 m. 
Effect of PGD 2 on DP and CRTH2 Expression in UPM
Finally, we investigated the effect of PGD 2 on DP and CRTH2 expression in UPM. Compared with buffer control, 10 -6 M of PGD 2 significantly enhanced the expression of DP mRNA (p = 0.028, fig. 8 a) . On the contrary, PGD 2 significantly reduced the expression of CRTH2 mRNA (p = 0.028, fig. 8 b) .
Discussion
In the present study, we examined DP and CRTH2 expression in sinonasal tissues from CRS patients with different conditions. We found that a variety of cells, including ciliated columnar epithelia, vascular endothelial cells, glands and infiltrating inflammatory cells, express DP mRNA in both UPM and NP. This result is consistent with the report by Nantel et al. [15] demonstrating that DP is expressed in epithelial goblet cells, serous glands, vascular endothelium, epithelium and some of the infiltrating inflammatory cells, including eosinophils, in nasal mucosa.
In NP, DP mRNA levels were significantly higher than in UPM. To the best of our knowledge, this is the first report showing elevated DP expression in inflamed human tissue although it is known that DP levels were increased following antigen challenge in a murine model of asthma [10] . Two possible explanations have arisen for the elevated DP level. First, this observation may be due to differences in the degree of infiltration of inflammatory cells expressing DP mRNA between UPM and NP, since infiltration of cells expressing DP mRNA was increased in NP, whereas expression of DP mRNA in constitutive cells seems to be similar when using ISH ( fig. 1 ) . Second, an increased PGD 2 level in middle meatus secretions may induce elevated DP expression since in the presence of PGD 2 , DP mRNA expression was significantly enhanced ( fig. 6 , 8 ) . DP-induced signals promote eosinophil survival and chemotaxis [13, 14] . Our results suggest that increased DP expression in the middle meatus may be associated with NP formation, since accumulation of activated eosinophils is a major hallmark of NP [2, 3] . In fact, DP plays a proinflammatory role in the pathogenesis of airway inflammation [18, 19] . Deletion of DP, for example, reduces the pathophysiology of asthma, including eosinophilic inflammation and Th 2 cytokine production, in mice [18] . In contrast to DP, CRTH2 was expressed mainly on infiltrated inflammatory cells in UPM. This result is consistent with the report showing that CRTH2 is selectively expressed on human immune cells, e.g. Th 2 -type T cells, eosinophils, basophils and a subset of monocytes [20] . Nantel et al. [15] demonstrated that CRTH2 was expressed in eosinophils and T cells in NP. In the present study, some of the glands also expressed CRTH2 mRNA. Expression of CRTH2 in glands may be associated with recent findings that administration of CRTH2 antagonists attenuates mucous cell hyperplasia [21] . Interestingly, CRTH2 mRNA levels in NP were significantly lower than those of UPM. The role of CRTH2 in allergic airway inflammation in vivo remains controversial [22] . CRTH2 participates in the recruitment of eosinophils from the bone marrow into the bloodstream, airway eosinophilia and hyperresponsiveness [23] [24] [25] [26] , suggesting that CRTH2 plays a proinflammatory role in vivo. Following repeated intranasal sensitization with pollen allergen in a murine model of pollinosis, CRTH2 gene-deficient mice had significantly weaker allergenspecific IgE/IgG 1 production, nasal eosinophilia and IL-4 production by submandibular lymph node cells than wild-type mice [26] . In addition, there are several reports demonstrating that pharmacological blockade of CRTH2 leads to reduced allergic responses [21, 26, 27] . For example, administration of CRTH2 antagonists attenuates peribronchial eosinophilia [21] . On the contrary, mice deficient in CRTH2 show increased eosinophil recruitment and IL-5 production by splenocytes in an asthma model, suggesting that CRTH2 mediates anti-inflammatory signals [28] . However, the above-described anti-inflammatory effect of CRTH2 most likely reflects CRTH2 expression in Th 1 cells in mice, which is in contrast to human cells.
One possible explanation for the lower CRTH2 levels in NP compared with UPM is that down-modulation of CRTH2 expression occurs in NP. Several reports have demonstrated the down-modulation upon activation [10, [29] [30] [31] . CRTH2 expression on human Th 2 cells was reduced upon CD3/CD28 stimulation [29] and on human eosinophils upon either PGD 2 or IL-5 activation [30] . In addition, CRTH2 levels in lung tissue decreased following antigen challenge in a murine model of asthma [10] . More recently, down-modulation of CRTH2 by PGD 2 was mediated with G protein-coupled receptor kinases CRK2, GRK5 or CRK6 [31] . We revealed that there are two distinct populations: one population with high CRTH2 expression, mainly CRS patients without NP, and the other with low CRTH2 expression and higher h-PGDS expression ( fig. 5 ). There was less CRTH2 mRNA in radiologically more severe cases of CRS. In addition, functional analysis demonstrated that the presence of PGD 2 significantly reduced the expression of CRTH2 in UPM. These results, which are similar to the above reports, support the possibility that the elevated production of PGD 2 via the action of h-PGDS may induce a reduction in CRTH2 expression in NP. Also, down-modulation of CRTH2 on inflammatory cells may keep them in NP, leading to the augmentation of local inflammation.
The magnitude of the decrease in CRTH2 mRNA after incubation with PGD 2 is modest, suggesting that the effect of PGD 2 is not the only mechanism at play. Levels of CRTH2 mRNA were inversely correlated with IL-5 and eotaxin levels. These results suggest that down-modulation of CRTH2 mRNA may be regulated not only by PGD 2 itself but also by eosinophil-associated cytokines/ chemokines, especially eotaxin.
The present findings were not similar to our previous report investigating the expression of DP and CRTH2 in the inferior turbinates [32] . In that paper, CRTH2 mRNA expression in inferior turbinates from patients with allergic rhinitis was significantly higher than in control subjects without mucosal hypertrophy. In addition, CRTH2 levels were significantly and positively correlated with the degree of eosinophil infiltration into inferior turbinates. This discrepancy may be due to different sites of the nose studied (middle meatus mucosae versus inferior turbinates) and/or different conditions (CRS versus allergic rhinitis). These findings may support the possibility that the selective down-modulation of CRTH2 in middle meatus mucosae may be associated with NP formation, since NP formation was rarely seen in inferior turbinates.
In conclusion, the present study shows that the upregulation of DP and the down-regulation of CRTH2 are closely associated with the pathophysiology of CRS, e.g. NP formation. These results suggest that the control of both DP and CRTH2 signaling is a potential therapeutic target for the treatment of CRS. Our findings also suggest that the expression of DP and CRTH2 in sinonasal tissues is directly and indirectly regulated by PGD 2 . CRS is known as 'asthma of the upper airway' due to similarities in the pathogenesis of the two conditions; therefore, the therapeutic potential of regulating adequate DP/ CRTH2 signaling might also extend to the treatment of asthma.
